"Pyridines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
| Descriptor ID |
D011725
|
| MeSH Number(s) |
D03.383.725
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyridines".
Below are MeSH descriptors whose meaning is more specific than "Pyridines".
This graph shows the total number of publications written about "Pyridines" by people in this website by year, and whether "Pyridines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 0 | 1 | 1 |
| 1994 | 1 | 2 | 3 |
| 1995 | 1 | 2 | 3 |
| 1996 | 1 | 0 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 2 | 3 |
| 1999 | 1 | 1 | 2 |
| 2000 | 4 | 1 | 5 |
| 2001 | 2 | 5 | 7 |
| 2002 | 2 | 0 | 2 |
| 2003 | 0 | 3 | 3 |
| 2004 | 1 | 4 | 5 |
| 2005 | 1 | 7 | 8 |
| 2006 | 4 | 1 | 5 |
| 2007 | 5 | 4 | 9 |
| 2008 | 5 | 2 | 7 |
| 2009 | 9 | 4 | 13 |
| 2010 | 14 | 4 | 18 |
| 2011 | 11 | 2 | 13 |
| 2012 | 6 | 5 | 11 |
| 2013 | 5 | 4 | 9 |
| 2014 | 6 | 3 | 9 |
| 2015 | 7 | 2 | 9 |
| 2016 | 8 | 5 | 13 |
| 2017 | 4 | 5 | 9 |
| 2018 | 6 | 6 | 12 |
| 2019 | 1 | 6 | 7 |
| 2020 | 3 | 5 | 8 |
| 2021 | 6 | 6 | 12 |
| 2022 | 0 | 6 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pyridines" by people in Profiles.
-
Serine biosynthesis as a novel therapeutic target for dilated cardiomyopathy. Eur Heart J. 2022 09 21; 43(36):3477-3489.
-
Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors. Clin Cancer Res. 2022 08 02; 28(15):3214-3224.
-
Selpercatinib-Induced Hypothyroidism Through Off-Target Inhibition of Type 2 Iodothyronine Deiodinase. JCO Precis Oncol. 2022 06; 6:e2100496.
-
Pfizer and Palbociclib in China: Analyzing an Oncology Pay-for-Performance Plan. Value Health Reg Issues. 2022 Sep; 31:34-38.
-
A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer. Cancer Med. 2022 07; 11(14):2790-2800.
-
Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer. J Immunother Cancer. 2022 03; 10(3).
-
Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). J Clin Oncol. 2022 01 20; 40(3):282-293.
-
Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial. JAMA Oncol. 2021 Nov 01; 7(11):1669-1677.
-
Evaluation of Hedgehog Pathway Inhibitors as a Therapeutic Option for Uterine Leiomyosarcoma Using the Xenograft Model. Reprod Sci. 2022 03; 29(3):781-790.
-
Dose Optimization of Sotorasib: Is the US Food and Drug Administration Sending a Message? J Clin Oncol. 2021 11 01; 39(31):3423-3426.